Middle East Biobanks Market To Reach $1.52 Billion By 2033

Middle East Biobanks Market Growth & Trends

The Middle East biobanks market size is projected to reach USD 1.52 billion by 2033, growing at a CAGR of 6.34% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is expanding steadily, fueled by growing demand for advanced sample storage, preservation, and data management solutions to support precision medicine, genomic research, and translational healthcare. As regional governments accelerate investment in national genome projects, personalized medicine, and biotechnology infrastructure, biobanking has become a cornerstone for initiatives aimed at improving healthcare outcomes, advancing disease research, and enabling pharmaceutical innovation. Applications in genetic screening, biomarker discovery, drug development, and stem cell preservation are key drivers of market momentum across the region.

Technological progress in cryogenic storage systems, automated sample handling, Laboratory Information Management Systems (LIMS), and AI-driven data analytics is transforming biobanking operations' efficiency, accuracy, and scalability. At the same time, robust national programs such as the Emirati Genome Programme in the UAE and the Qatar Genome Programme, as well as rising collaborations between global biotech firms and local institutions, are strengthening the region's capacity and capabilities in biobanking.

With increasing focus on population health, regenerative medicine, and data-driven healthcare, the Middle East biobanks industry is well-positioned to play a pivotal role in the future of genomic and biomedical research. Continued investments in infrastructure, ethical and regulatory harmonization, and public-private partnerships will be vital in unlocking the full potential of biobanking technologies and positioning the region as a hub for precision medicine and innovation.

 Request a free sample copy or view report summary: Middle East Biobanks Market Report

Middle East Biobanks Market Report Highlights

• By product & services, services dominated the market in 2024, accounting for the largest revenue share. This large share attributed to the growing demand for sample collection, processing, storage, and advanced data management solutions has reinforced the strength of this segment. Value-added offerings such as genetic sequencing, biomarker analysis, and customized research support further highlight the importance of services in enabling precision medicine, clinical research, and pharmaceutical development across the region.

• By biospecimen, the human tissues segment captured the largest revenue share of 38.80% in 2024, driven by increasing demand for tissue samples in disease research, drug discovery, and personalized medicine. The rising prevalence of chronic conditions, particularly cancer, has fueled the need for high-quality human tissue samples to advance biomarker identification and regenerative medicine studies. Expanding regional biobank initiatives and collaborations with international research organizations continue to strengthen this segment’s dominance.

• By biobank, the physical/real biobanks segment dominated the market in 2024, reflecting the strong need for on-site storage of biological materials such as tissues, stem cells, blood, and DNA. Investments in advanced cryogenic storage systems, robotic handling, and digital tracking solutions have enhanced the efficiency and reliability of physical biobanks. Additionally, large-scale national genome projects and hospital-based biobanking facilities across the UAE, Qatar, and Saudi Arabia have reinforced this segment’s leadership.

• By application, the therapeutics segment accounted for the largest revenue share of 45.07% in 2024, supported by the increasing use of biobank samples in regenerative medicine, targeted therapies, and advanced drug development. Growing demand for personalized treatment approaches, coupled with the integrating genomic data into healthcare systems, has expanded the role of biobanks in therapeutic innovation. Collaborations between pharmaceutical companies, research institutes, and biobanks underscore this segment’s central position in driving market growth.

Middle East Biobanks Market Segmentation

Grand View Research has segmented the Middle East biobanks market based on product & services, biospecimen, biobanks, application, and country.

Middle East Biobanks Product & Services Outlook (Revenue, USD Million, 2021 - 2033)

• Product

  • Biobanking Equipment

    • Temperature Control Systems

      • Freezers & Refrigerators

      • Cryogenic Storage Systems

      • Thawing Equipment

    • Incubators & Centrifuges

    • Alarms & Monitoring Systems

    • Accessories & Other Equipment

  • Biobanking Consumables

  • Laboratory Information Management Systems

• Services

  • Biobanking & Repository

  • Lab processing

  • Qualification/ Validation

  • Cold Chain Logistics

  • Other Services

Middle East Biobanks Biospecimen Outlook (Revenue, USD Million, 2021 - 2033)

• Human Tissues

• Human Organs

• Stem Cells

  • Adult Stem Cells

  • Embryonic Stem Cells

  • IPS Cells

  • Other Stem Cells

• Other Biospecimens

Middle East Biobanks Outlook (Revenue, USD Million, 2021 - 2033)

• Physical/Real Biobanks

  • Tissue Biobanks

  • Population Based Biobanks

  • Genetic (DNA/RNA)

  • Disease Based Biobanks

• Virtual Biobanks

Middle East Biobanks Application Outlook (Revenue, USD Million, 2021 - 2033)

• Therapeutics

• Drug Discovery & Clinical Research

• Clinical Diagnostics

• Other Applications

Middle East Biobanks Country Outlook (Revenue, USD Million, 2021 - 2033)

• Middle East

  • Saudi Arabia

  • UAE

  • Kuwait

  • Qatar

  • Oman

  • Rest of Middle East

List of Key Players in the Middle East Biobanks Market

• Thermo Fisher Scientific Inc.

• Merck KGaA

• Qiagen

• Danaher Corporation

• Becton, Dickinson, and Company (BD)

• Taylor-Wharton

• Charles River Laboratories

• Lonza

• Stemcell Technologies

• Biovault Family